.png)
mohd izzuan
Madrigal Pharmaceuticals (NASDAQ:MDGL) traded ~10% higher on Tuesday after the Pennsylvania-based biotech posted a strong quarterly beat with its Q2 2025 results, thanks mainly to increased uptake for Rezdiffra, its FDA-approved treatment for a liver disease called MASH.
The company
English (US) ·